Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116554

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

C Serradeil-Le Gal, J Wagnon, C Garcia, C Lacour, P Guiraudou, B Christophe, G Villanova, D Nisato, J P Maffrand, and G Le Fur

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Serradeil-Le Gal, C. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Wagnon, J. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Garcia, C. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Lacour, C. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Guiraudou, P. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Christophe, B. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Villanova, G. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Nisato, D. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Maffrand, J. in: PubMed | Google Scholar

Sanofi Recherche, Biochimie Exploratoire, Toulouse, France.

Find articles by Le Fur, G. in: PubMed | Google Scholar

Published July 1, 1993 - More info

Published in Volume 92, Issue 1 on July 1, 1993
J Clin Invest. 1993;92(1):224–231. https://doi.org/10.1172/JCI116554.
© 1993 The American Society for Clinical Investigation
Published July 1, 1993 - Version history
View PDF
Abstract

SR 49059, a new potent and selective orally active, nonpeptide vasopressin (AVP) antagonist has been characterized in several in vitro and in vivo models. SR 49059 showed high affinity for V1a receptors from rat liver (Ki = 1.6 +/- 0.2) and human platelets, adrenals, and myometrium (Ki ranging from 1.1 to 6.3 nM). The previously described nonpeptide V1 antagonist, OPC-21268, was almost inactive in human tissues at concentrations up to 100 microM. SR 49059 exhibited much lower affinity (two orders of magnitude or more) for AVP V2 (bovine and human), V1b (human), and oxytocin (rat and human) receptors and had no measurable affinity for a great number of other receptors. In vitro, AVP-induced contraction of rat caudal artery was competitively antagonized by SR 49059 (pA2 = 9.42). Furthermore, SR 49059 inhibited AVP-induced human platelet aggregation with an IC50 value of 3.7 +/- 0.4 nM, while OPC-21268 was inactive up to 20 microM. In vivo, SR 49059 inhibited the pressor response to exogenous AVP in pithed rats (intravenous) and in conscious normotensive rats (intravenous and per os) with a long duration of action (> 8 h at 10 mg/kg p.o). In all the biological assays used, SR 49059 was devoid of any intrinsic agonistic activity. Thus, SR 49059 is the most potent and selective nonpeptide AVP V1a antagonist described so far, with marked affinity, selectivity, and efficacy toward both animal and human receptors. With this original profile, SR 49059 constitutes a powerful tool for exploring the therapeutical usefulness of a selective V1a antagonist.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 224
page 224
icon of scanned page 225
page 225
icon of scanned page 226
page 226
icon of scanned page 227
page 227
icon of scanned page 228
page 228
icon of scanned page 229
page 229
icon of scanned page 230
page 230
icon of scanned page 231
page 231
Version history
  • Version 1 (July 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts